

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sanai Health Industry Group Company Limited

三愛健康產業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

PROFIT WARNING

This announcement is made by Sanai Health Industry Group Company Limited (the “**Company**“, together with its subsidiaries, collectively the “**Group**”) in accordance with Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that, based on the currently available information and the preliminary review of the unaudited management accounts of the Group for the year ended 31 December 2023 (the “**Reporting Period**”), it is expected that the Group will record a significant decrease in revenue and gross profit margin, which resulted in the substantial decrease in net profit attributable to the owner of the Company of not more than 40% as compared with that for the corresponding period of 2022.

The significant decrease in revenue and gross profit margin was mainly attributable to the decrease in sales volume of self-manufactured pharmaceutical products and substantial increase in the general costs of traditional Chinese herb materials in the PRC during the Reporting Period.

The Company is still in the process of finalizing the annual results of the Group for the year ended 31 December 2023. The information disclosed in this announcement represents a preliminary assessment by the Board based on the information currently available to it, which has not yet reviewed by the audit committee of the Board nor audited by the auditor of the Company. Hence, the annual results of the Group for the year ended 31 December 2023 may be different from the information disclosed herein.

By Order of the Board
Sanai Health Industry Group Company Limited
SHE Hao
Executive Director

Hong Kong, 25 March 2024

As at the date of this announcement, the Board comprises five executive directors, namely, Mr. Chen Chengqing, Mr. Gao Borui, Mr. Yuan Chaoyang, Professor Zhang Rongqing and Mr. She Hao, one non-executive director, namely, Mr. Xiu Yuan and three independent non-executive directors, namely, Professor Zhu Yi Zhun, Mr. Khor Khie Liem Alex and Mr. Zhang Ruigen.